Literature DB >> 19565916

Ethics of cancer gene transfer clinical research.

Jonathan Kimmelman1.   

Abstract

Cancer gene transfer is a relatively novel intervention strategy. In part because of this novelty, trials often present greater uncertainties than those investigating more conventional approaches. In the following review, I examine how this greater uncertainty might affect how clinical studies are designed, when they are initiated, their degree of risk, and whether such risk can be justified in terms of therapeutic benefit. The review also discusses two other ethical issues presented by gene transfer clinical research: fairness in subject selection and communications with the public. I conclude with a series of recommendations directed toward researchers, policymakers, and ethics committee members.

Entities:  

Mesh:

Year:  2009        PMID: 19565916     DOI: 10.1007/978-1-59745-561-9_23

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

2.  Ocular gene transfer in the spotlight: implications of newspaper content for clinical communications.

Authors:  Shelly Benjaminy; Tania Bubela
Journal:  BMC Med Ethics       Date:  2014-07-16       Impact factor: 2.652

3.  "Is a cure in my sight?" Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials.

Authors:  Shelly Benjaminy; Ian Macdonald; Tania Bubela
Journal:  Genet Med       Date:  2013-09-26       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.